Abstract: Methods and compositions for male or female contraception are provided. The compositions include an effective amount of netrin-1 to reduce or inhibit sperm concentration in semen of males or to inhibit or reduce fusion of male gametes with female gametes in a female subject Still another embodiment provides a method for diagnosing male infertility by determining the amount of netrin-1 in a sample of epididymal fluid or semen from a male subject, comparing the amount of netting-1 in the sample to levels of netrin-1 in samples of epididymal fluid or semen from fertile males, wherein levels of netrin-1 in the sample from the male subject that are higher or lower than levels of netrin-1 in samples from fertile males are indicative of male infertility in the male subject.

Abstract: Modulating the interaction between ErbB2 and Erbin is an effective method for treating one or more symptoms of ErbB2-mediated disorders. It has been discovered that Erbin stabilizes ErbB2 in vivo and inhibiting the formation of heterodimers between Erbin and ErbB2 reduces or inhibits the biological activity of ErbB2 relative to control levels. Reducing the biological activity of ErbB2 is useful in the treatment of conditions characterized by the overexpression or misregulation of ErbB2. These conditions include, but are not limited to breast cancer and prostate cancer. Alternatively, agonist of Erbin that promote or enhance the interaction of Erbin with ErbB2 can be useful in the treatment of certain neurological disorders. It has also been discovered that Erbin plays a role in the myelination of neurons of the peripheral nervous system.

Abstract: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.

Abstract: Methods and compositions for modulating GABA release in a subject are provided. A preferred embodiment provides a composition containing an effective amount of an ErbB4 ligand to enhance or promote GABA release, i.e., GABAergic transmission. The ErbB4 ligand can be an agonist ligand or an antagonist ligand depending on the disorder to be treated. Methods for treating neurological disorders are also provided. Representative disorders that can be treated include, but are not limited to schizophrenia, epilepsy, depression and anxiety, insomnia, stroke, pain, bipolar, autism, or a combination thereof. By increasing GABA release a sedative effective can be induced in the subject. Methods for inducing a stimulatory effect in a subject are also provided. In these methods, an effective amount of an ErbB4 antagonist ligand is administered to the subject to reduce or inhibit GABA release in the subject.

Abstract: A battery car anti-theft device, which is mainly characterized in utilizing an electronic control circuit to control the external power supply state of a battery, and when set in the anti-theft state, if it is detected that the supply current is greater than a preset value, then the entire external power supply of the battery is immediately cut off, thus, there is no power supply to start the engine to enable the car thief to drive the vehicle away, thereby achieving the objective of preventing the vehicle from being stolen.

Abstract: Modulating the interaction between ErbB2 and Erbin is an effective method for treating one or more symptoms of ErbB2-mediated disorders. It has been discovered that Erbin stabilizes ErbB2 in vivo and inhibiting the formation of heterodimers between Erbin and ErbB2 reduces or inhibits the biological activity of ErbB2 relative to control levels. Reducing the biological activity of ErbB2 is useful in the treatment of conditions characterized by the overexpression or misregulation of ErbB2. These conditions include, but are not limited to breast cancer and prostate cancer. Alternatively, agonist of Erbin that promote or enhance the interaction of Erbin with ErbB2 can be useful in the treatment of certain neurological disorders. It has also been discovered that Erbin plays a role in the myelination of neurons of the peripheral nervous system.

Abstract: Methods and compositions for male or female contraception are provided. The compositions include an effective amount of netrin-1 to reduce or inhibit sperm concentration in semen of males or to inhibit or reduce fusion of male gametes with female gametes in a female subject Still another embodiment provides a method for diagnosing male infertility by determining the amount of netrin-1 in a sample of epididymal fluid or semen from a male subject, comparing the amount of netting-1 in the sample to levels of netrin-1 in samples of epididymal fluid or semen from fertile males, wherein levels of netrin-1 in the sample from the male subject that are higher or lower than levels of netrin-1 in samples from fertile males are indicative of male infertility in the male subject.

Abstract: Methods and compositions for modulating GABA release in a subject are provided. A preferred embodiment provides a composition containing an effective amount of an ErbB4 ligand to enhance or promote GABA release, i.e., GABAergic transmission. The ErbB4 ligand can be an agonist ligand or an antagonist ligand depending on the disorder to be treated. Methods for treating neurological disorders are also provided. Representative disorders that can be treated include, but are not limited to schizophrenia, epilepsy, depression and anxiety, insomnia, stroke, pain, bipolar, autism, or a combination thereof. By increasing GABA release a sedative effective can be induced in the subject. Methods for inducing a stimulatory effect in a subject are also provided. In these methods, an effective amount of an ErbB4 antagonist ligand is administered to the subject to reduce or inhibit GABA release in the subject.

Abstract: A disk drive is disclosed comprising a disk and a head actuated radially over the disk. The head is positioned over a first radial location, and a first data tracks per inch (TPI—1) is selected for data tracks recorded near the first radial location. The head is positioned over a second radial location, and a second data tracks per inch (TPI—2) is selected for data tracks recorded near the second radial location. The head is positioned over a third radial location, and a third data tracks per inch (TPI—3) is selected for data tracks recorded near the third radial location. A geometry of the head is estimated in response to TPI—1, TPI—2 and TPI—3.

Abstract: The present invention provides an auxiliary luminous trim strip of a car lamp. The trim strip has a long strip body, a car lamp mating surface mating with the surface of the car lamp, a light-emitting surface, placed in front of the strip body, a locating component, used to locate the strip body and car lamp, a plurality of luminous bodies, assembled onto the light-emitting surface in a predefined configuration, and a power supply portion, used to supply power required for the luminous bodies. The luminous trim strip generates a trimming effect by the color, texture and shape of the strip body and enhances illumination intensity through the light emission of the luminous bodies, further enhancing the warning effect of the car lamp.

Abstract: A method of operating a disk drive including providing the disk drive. The disk drive includes a disk with data tracks and an actuator with a slider including a perpendicular magnetic write head. The write head includes leading and trailing sides defining a taper angle. The write head and the actuator define a maximum skew angle with respect to the data tracks. The maximum skew angle being greater than the taper angle. The method further includes rotating the slider during operation of the disk drive to reduce a difference between the skew and taper angles for aligning the write head with the data tracks.

Abstract: The present invention provides a deflector with a positioning device for a car including a deflector unit with two ends, a fastener unit, a connecting unit, and a supporting unit. Each end of the deflector unit has at least two sliding grooves installed on the car body with the connecting unit and fastener unit. The fastener unit includes two fastener plates and a positioning component. The connecting unit includes two connecting bars and a universal joint, each connecting bar being fastened to the first and second connecting ends of the sliding groove of the deflector unit. The other end of the connecting bar has a fastening bar section, which can fasten to the fastening edge of the fastener plate. The supporting unit is set between the deflector unit and car body for a buffering effect. The invention allows for convenient assembly and installation without drilling, while maintaining stability and practicality.

Abstract: A method characterizes a generally-trapezoidally-shaped portion of a writing pole of a perpendicular magnetic write head in proximity to a magnetic medium. The method includes providing measured track width data corresponding to magnetic track widths of a plurality of tracks written by the writing pole on a rotating magnetic medium underlying the writing pole. The magnetic track widths vary as a function of skew angle of the writing pole during writing. The method further includes determining a magnetic width of the wider of a leading edge and a trailing edge of the writing pole from a first portion of the measured track width data corresponding to a first range of skew angles. The method further includes determining at least one magnetic taper angle of the writing pole from the measured track width data.

Abstract: The instant invention provides a method of inhibiting proliferation of maligant cells by administration of a Ras-activity inhibitory effective amount of DNA which encodes the protein Erbin into the maligant cells.